Alzheimer's disease is a terminal neurodegenerative disease that has historically been diagnosed based on observing significant memory loss. There is currently no cure or disease-modifying therapy for this terminal illness, despite hundreds of clinical trials. It is thought these trials may have a high failure rate because the people enrolled are in the latest stages of the disease, likely already suffering a level of brain tissue loss that cannot easily be repaired. Thus, researchers have put their mind to how to detect this disease earlier, while a chance may still exist to slow its progression. Recent research has shown a biological marker associated with the disease, a peptide called amyloid-beta, changes decades before any memory-related issues are apparent.
Mar-13-2019, 12:29:34 GMT